Clinical trials

  • NIVOLUMAB for Melanoma|Unresectable stage III melanoma|Metastatic melanoma
  • DOSTARLIMAB for Head and neck squamous cell carcinoma (HPV-negative)
  • LONCASTUXIMAB TESIRINE for Diffuse large B-cell lymphoma (DLBCL) | High-grade B-cell lymphoma (HGBCL)
  • Sonidegib for Locally advanced basal cell carcinoma
  • Retroviral vector containing the common gamma chain cDNA; Autologous tumour-infiltrating lymphocytes for Advanced melanoma | Head and neck squamous cell carcinoma
  • VISUGROMAB for Non-small cell lung cancer (non-squamous, metastatic)
  • NIVOLUMAB for Unresectable melanoma | Metastatic melanoma
  • VISUGROMAB for Non-small cell lung cancer (non-squamous) | Metastatic non-small cell lung cancer
  • AZD0901 for Gastroesophageal adenocarcinoma
  • Glofitamab for Aggressive B-cell non-Hodgkin lymphoma (relapsed/refractory) | Diffuse large B-cell lymphoma (DLBCL) (relapsed/refractory) | High-grade B-cell lymphoma (relapsed/refractory)
  • POMALIDOMIDE for Smoldering multiple myeloma (high risk of progression to symptomatic myeloma)
  • Osimertinib for Non-small cell lung cancer (stage IV)